205 related articles for article (PubMed ID: 23285138)
1. Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma.
Matulis SM; Morales AA; Yehiayan L; Lee KP; Cai Y; Boise LH
PLoS One; 2012; 7(12):e52662. PubMed ID: 23285138
[TBL] [Abstract][Full Text] [Related]
2. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
Matulis SM; Morales AA; Yehiayan L; Croutch C; Gutman D; Cai Y; Lee KP; Boise LH
Mol Cancer Ther; 2009 May; 8(5):1197-206. PubMed ID: 19417148
[TBL] [Abstract][Full Text] [Related]
3. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
Wang R; Liu C; Xia L; Zhao G; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2012 Dec; 18(24):6690-701. PubMed ID: 23082001
[TBL] [Abstract][Full Text] [Related]
4. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo.
Zhou P; Kalakonda N; Comenzo RL
Br J Haematol; 2005 Mar; 128(5):636-44. PubMed ID: 15725085
[TBL] [Abstract][Full Text] [Related]
5. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma.
Morales AA; Gutman D; Lee KP; Boise LH
Blood; 2008 May; 111(10):5152-62. PubMed ID: 18354037
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.
Wu X; Shi J; Wu Y; Tao Y; Hou J; Meng X; Hu X; Han Y; Jiang W; Tang S; Zangari M; Tricot G; Zhan F
Cancer Biol Ther; 2010 Dec; 10(11):1201-14. PubMed ID: 20953137
[TBL] [Abstract][Full Text] [Related]
7. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
[TBL] [Abstract][Full Text] [Related]
8. [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research].
Zhou XJ; Zhou YH; Chen XH; Qian WB
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):834-9. PubMed ID: 23980369
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.
Doudican NA; Wen SY; Mazumder A; Orlow SJ
Oncol Rep; 2012 Nov; 28(5):1851-8. PubMed ID: 22922937
[TBL] [Abstract][Full Text] [Related]
10. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
Wen J; Cheng HY; Feng Y; Rice L; Liu S; Mo A; Huang J; Zu Y; Ballon DJ; Chang CC
Br J Haematol; 2008 Jan; 140(2):169-80. PubMed ID: 18173754
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.
Zhao H; Guo W; Peng C; Ji T; Lu X
Mol Biol Rep; 2010 Jun; 37(5):2509-15. PubMed ID: 19701692
[TBL] [Abstract][Full Text] [Related]
12. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
13. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
14. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
Ramos AM; Aller P
Biochem Pharmacol; 2008 May; 75(10):1912-23. PubMed ID: 18359480
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.
Kircelli F; Akay C; Gazitt Y
Int J Oncol; 2007 Apr; 30(4):993-1001. PubMed ID: 17332940
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells.
McCafferty-Grad J; Bahlis NJ; Krett N; Aguilar TM; Reis I; Lee KP; Boise LH
Mol Cancer Ther; 2003 Nov; 2(11):1155-64. PubMed ID: 14617789
[TBL] [Abstract][Full Text] [Related]
17. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
[TBL] [Abstract][Full Text] [Related]
18. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
Kajiguchi T; Yamamoto K; Iida S; Ueda R; Emi N; Naoe T
Cancer Sci; 2006 Jun; 97(6):540-5. PubMed ID: 16734734
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs.
Meister MT; Boedicker C; Graab U; Hugle M; Hahn H; Klingebiel T; Fulda S
Cancer Lett; 2016 Oct; 381(2):287-95. PubMed ID: 27521572
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity.
Zheng CY; Lam SK; Li YY; Ho JC
Int J Oncol; 2015 Mar; 46(3):1067-78. PubMed ID: 25572414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
